Key Takeaways
- Revenue up 29% YoY, but high-cost inventory eroded profits: EBITDA grew 40% YoY to ₹21.3 crore, yet management stated profits would have been "much healthier" without consuming ~₹60 crore of high-cost inventory during the quarter.
- Dahej expansion is live but empty: Commercial production began from the newly expanded facility, doubling reactor capacity to 500 KL, but utilization on the expanded portion is expected to drop to just 30–35% after September before a ramp-up begins.
- Pricing pressure is broad but may be bottoming: Flame retardant prices have corrected ~60%, and PTC faces irrational competition, yet management noted prices have stabilized or shown slight upward movement in recent weeks.
- Electrolyte salts and SDA are the FY25 story, not FY24: Management called FY25 the "key turning point" for electrolytes, while SDA demand is expected to ramp only from November 2023 onward, pushing a favourable margin shift to Q4.
- What to watch next quarter: Whether the four new products in plant-scale trials secure customer approvals on schedule, whether the QIP process completes, and whether the promised margin recovery toward October/November actually materializes.
Dahej Expansion & Capacity Utilization
- Capacity doubled, now waiting for orders: Installed reactor capacity increased from 294 KL to 500 KL, and assembly lines rose from 27 to 39, but the company is currently executing only one container each of plant-scale trial material for new products, leaving the expanded facility largely idle.
- Utilization will dip before it climbs: Temporary high occupancy from four new products running plant-scale trials will end by late August or early September, after which utilization on the expanded capacity will drop to about 30–35%.
- Ramp-up tied to customer validations: The company expects to start utilizing the expanded capacity at substantial levels from December 2023, contingent on customer approvals for the products currently in trials.
- 80–85% utilization targeted for next fiscal year: Management expects to hit that level in the next financial year, with the assembly side reaching 65–70% utilization from November of this year.
- Depreciation headwind is now locked in: The ~₹235 crore Dahej spend was capitalized this quarter, so the higher depreciation provision will remain at the same quarterly level throughout the year.
Margin Walk & Inventory Overhang
- The headline margin improvement masks inventory pain: EBITDA margin improved 145 bps YoY to 18.7%, driven by a 7.53% YoY decline in other expenses, but this was partially offset by higher COGS and employee costs.
- Two-thirds of legacy inventory consumed: The company consumed ~₹60 crore worth of high-cost finished goods and work-in-progress inventory out of ~₹90–92 crore held as of March 31, 2023, eroding profits during the quarter.
- ~₹30–32 crore of residual pain remains: Management stated the company is "nearly through" clearing high-priced SDA inventory, with the remaining ~₹30–32 crore expected to have some impact before margins normalize.
- Gross margin recovery expected by October/November 2023: Management believes gross margins can return to earlier levels (~55%) "quite soon," citing that the previous quarter's depressed margins were an anomaly caused by being caught with high SDA inventory when prices collapsed.
- Current margins are the benchmark until December: Until the Dahej plant gets better utilized, current EBITDA margins should be considered a baseline, with upward revision expected as commercial production fills the expanded capacity.
Chintan Shah: "We are still in a process of clearing of that high priced inventory so we are nearly through, so we almost consumed potentially Rs.60 crore worth of that inventory in this quarter and we still might have about Rs.30 crore, Rs.32 crore of residual inventory, so this might have some impact, but yes we can look at getting back to the earlier levels quite soon. I believe October, November 2023 should be that point."
Segment-Level Demand & Pricing
SDA (Structure Directing Agents)
- China remains the drag: Heavy-duty vehicle sales in China, the large end-market, have not returned to full scale, keeping SDA demand depressed despite steady increases.
- Two paused products have resumed: Products from two large customers that were on hold started in July 2023, with the next dispatch scheduled for September.
- Recovery timeline is back-half loaded: Management expects flattish levels until October, then "very good growth" beginning in November 2023, with formal approvals for two products expected in a couple of months and two more by year-end.
Electrolyte Salts
- Two new customers progressing toward commercialization: Lab-scale approval on the electrolyte solution is complete; the company is now working toward pilot-scale trials, with the first trial order targeted for delivery from Dahej by October 2023.
- One large customer resumed offtake in June: A customer whose orders were on hold restarted purchasing during the quarter.
- FY25 is the stated turning point: Management expects commercial activity to begin in December 2023, with 2024 as a good year, but emphasized that 2025 will be the "turnaround year" driven by exponentially growing demand for energy storage systems.
Chintan Shah: "We have been in this segment since 2013. It is a long-drawn process and again this is an equally strong entry barrier area for SDA because any change in quality parameters or any abnormality can lead to incidences with the battery. So, once you are qualified and the quality is accepted then it becomes really a very strong entry barrier area for the competition to get into it."
Flame Retardants
- Demand remains extremely subdued globally: Prices have corrected nearly 60% due to very weak demand, though raw material prices have also dropped significantly.
- Prices may have bottomed: Management noted that prices have stabilized or marginally improved after the quarter ended, calling current levels "unrealistically low" and unsustainable.
- Slow start planned from September 2023: The company expects ₹25–40 crore in revenue from flame retardants during this financial year.
PASC & PTC
- PASC remains stable with no demand erosion: Except for one PTC supply postponement in agrochemicals by a couple of months, the PASC segment has seen no order deferrals, protected by one-on-one customer relationships developed from the PTC segment.
- Price pressure exists but margins are protected: Customers are attempting to pass on margin pressure, but the company has tied PTC business to a raw-material-pricing-based model with large customers, keeping margins intact.
- Competitive dumping in PTC: Multiple domestic and Chinese competitors are dumping products just to generate revenue without regard for profit.
Chintan Shah: "This is kind of an unrealistically low pricing level and it is not sustainable for a long time and pricing pressure in lot of product or segments though we are fortunate that in certain PASC products where we are working one-on-one with the customer or on SDA and electrolytes also had entry barriers are really strong."
New Product Pipeline & Technology
- Four new products on the plant floor for the first time: Two agrochemical products and two pharmaceutical products are being produced at plant scale for customer validation.
- Continuous flow technology deployed on one new product: The company successfully implemented its continuous flow process to selectively remove an impurity and achieve high purity levels in a cost-effective and environmentally friendly manner.
- Monoglyme piloting begins: After overcoming obstacles across equipment and catalyst fronts, piloting of Monoglyme on a continuous flow basis is now starting.
- Metal extraction products entering commercial supply: Commercial supply begins this month.
- Agrochemical commercialization targeted for late December/early January: Post-approval, commercial supplies of the two agrochemical products are expected to begin around that timeframe.
- Pharma intermediates are an early-2025 story: The two pharmaceutical products currently in validation are expected to begin commercial business in early 2025, alongside a third pharma intermediate also in plant-scale production.
- Ultra-high-purity chemicals for semiconductors in development: Management disclosed an ambitious development project for a key starting material for semiconductor and IC manufacturing, noting that if successful, the company would be the only producer of this material in India. One potential Indian customer setting up a plant expects commercial production by late 2024, and the company is already in the qualification process.
Chintan Shah: "This can actually if we do this potentially then we would be the only producer of this key starting material for semiconductor in India."
Balance Sheet & Fundraising
- Interest costs remain elevated: High finance costs are driven by increased benchmark rates and high utilization of working capital facilities; the last scheduled repayment of existing term loans falls in Q1 of the next fiscal year.
- Employee costs rising with headcount: Costs increased due to new recruitments for the expanded Dahej facility, with more headcount additions planned during Q2.
- Logistics costs have normalized: Steadily reduced to realistic levels, providing a breather.
- QIP of ₹200 crore in process: The company is raising funds via a qualified institutional placement, with shareholder approval being sought. New shares will be issued, and the promoter stake will fall below 75% to comply with SEBI guidelines.
- Green chemistry investments underway: The newly expanded plant uses gravity-enabled production-to-packing with minimal human intervention, recovers and reuses nearly 80% of high-volume solvents, and is transitioning from LDO to natural gas at Dahej to reduce emissions.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Gross margin recovery | Return to earlier levels (~55%) | October/November 2023 |
| Dahej expanded capacity utilization | Reach 65–70% on assembly side | From November 2023 |
| Dahej expanded capacity utilization | Reach 80–85% | Next financial year |
| Electrolyte salts pilot trial | Deliver first trial order from Dahej plant | By October 2023 |
| Electrolyte salts commercial activity | Commercial volumes to begin | December 2023 |
| SDA demand ramp-up | Stronger demand, formal approvals for 2 products | By end of 2023 |
| Agrochemical new products | Commercial supplies begin post-approval | Late December 2023 / early January 2024 |
| Pharma intermediates (3 products) | Commercial business begins post-validation | Early 2025 |
| Flame retardants revenue | ₹25–40 crore | FY24 |
| Environmental clearance for new land | Receive permission | Potentially August 2023 |
| QIP fundraising | Raise ₹200 crore; promoter stake below 75% | In process |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Revenue from operations | ₹114.4 cr, +29% YoY from ₹88.4 cr |
| EBITDA | ₹21.3 cr, +40% YoY from ₹15.2 cr |
| EBITDA margin | 18.7%, +145 bps YoY from 17.2% |
| PAT | ₹9.5 cr, -3% YoY from ₹9.8 cr |
| PAT margin | 8.3% vs 11.1% in Q1 FY23 |
| Exports | ₹88.9 cr, 78% of revenue from operations |
| Other income | ₹1 cr, -46% YoY |
| COGS | +5.68% YoY |
| Employee benefit expenses | +0.40% YoY |
| Other expenses | -7.53% YoY |
| Depreciation | ₹6 cr vs ₹2.3 cr in Q1 FY23, +1.5% YoY |
| SDA segment revenue | ₹49.6 cr, ~43% of revenue |
| PTC segment revenue | ₹31.6 cr, ~28% of revenue |
| Pharma and Agro Intermediates and Specialty Chemicals revenue | ₹31 cr, ~27% of revenue |
| Electrolyte Salts revenue | ₹1.3 cr, ~1% of revenue |
| Installed reactor capacity | 500 kL, up from 294 kL; assembly lines increased from 27 to 39 |
| Inventory (excl. spares and packing) | ₹120 cr as on June 2023, down ~₹12.5 cr from ₹132.5 cr as on March 2023 |
| WIP & FG inventory consumed during quarter | ~₹60 cr, nearly two-thirds of ₹90–92 cr as on March 31, 2023 |
| Working capital utilization | 71% of total sanction limits of ₹220 cr |
| IPO proceeds utilized | ₹200.2 cr of ₹207.28 cr net proceeds, 97% utilized as on June 30, 2023 |
| Flame retardant revenue guidance FY24 | ₹25–40 cr |
| Flame retardant price reduction | ~60% from peak |
| QIP fundraising target | ₹200 cr |
| Next phase capex | Not more than ₹250 cr |
| Dahej expansion capitalized | ₹235 cr, 20-year assumed lifespan |
| Annual depreciation on all fixed assets | ~₹24 cr |
| Existing capacity utilization (pre-expansion) | Near full |
| New capacity utilization (reactor side) | Fully occupied temporarily, expected to drop to 30–35% by early September 2023 |
| New capacity utilization (assembly side) | Not yet started, expected 65–70% from November 2023 |
| Expected capacity utilization (overall) | 80% within next year |